Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 22 Apr 2021
The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors
20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...
Posted by Michael Wonder on 29 Nov 2020
Will COVID-19 vaccines be cost effective—and does it matter?
26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...
Posted by Michael Wonder on 23 Oct 2020
Efficiency ratio and rocketing drug prices: old concerns and new possibilities
23 October 2020 - One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at ...
Posted by Michael Wonder on 12 Jul 2020
Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?
10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets. ...
Posted by Michael Wonder on 17 Jan 2020
Pricing of pharmaceuticals is becoming a major challenge for health systems
13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...
Posted by Michael Wonder on 17 Jan 2020
Defining the concept of fair pricing for medicines
13 January 2020 - Suerie Moon and colleagues consider what makes a fair price for both buyers and sellers. ...
Posted by Michael Wonder on 22 Nov 2019
The life improvement value: a new measure of cost-efficiency
23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...
Posted by Michael Wonder on 27 Jul 2019
A non-inferiority framework for cost-effectiveness analysis
24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 05 Mar 2019
Future unrelated medical costs need to be considered in cost effectiveness analysis
5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...